Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen M Coley

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Phytochemistry|June 15, 2010
Cembranolides from the stem bark of the southern African medicinal plant, Croton gratissimus (Euphorbiaceae)Dulcie A Mulholland, Moses K Langat, Neil R Crouch, et al.
Gynecologic Oncology|April 26, 2002
Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancerGrazyna M Lewandowicz, Paul Britt, Alena W Elgie, et al.
Cancer Genomics & Proteomics|December 30, 2016
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated ProteinsIsa N Cruz, Helen M Coley, Holger B Kramer, et al.
European Journal of Haematology|September 10, 2009
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasiaEleftheria Hatzimichael, Aggeliki Dasoula, Reshma Shah, et al.
British Journal of Cancer|February 16, 2019
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinomaDavid J Pinato, Matthew W Brown, Sebastian Trousil, et al.
Leukemia Research|May 9, 2009
Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasiaEleftheria Hatzimichael, Leonidas Benetatos, Aggeliki Dasoula, et al.
ACS Nano|April 13, 2010
Higher dispersion efficacy of functionalized carbon nanotubes in chemical and biological environmentsElena Heister, Constanze Lamprecht, Vera Neves, et al.
Anticancer Research|May 23, 2002
Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility studyHelen M Coley, Jean M Sargent, Christine J Williamson, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Anticancer Research|May 16, 2009
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancerPrasanna Sooriakumaran, Helen M Coley, Stephen B Fox, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Phytochemistry|June 15, 2010
Cembranolides from the stem bark of the southern African medicinal plant, Croton gratissimus (Euphorbiaceae)Dulcie A Mulholland, Moses K Langat, Neil R Crouch, et al.
Gynecologic Oncology|April 26, 2002
Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancerGrazyna M Lewandowicz, Paul Britt, Alena W Elgie, et al.
Cancer Genomics & Proteomics|December 30, 2016
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated ProteinsIsa N Cruz, Helen M Coley, Holger B Kramer, et al.
European Journal of Haematology|September 10, 2009
The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasiaEleftheria Hatzimichael, Aggeliki Dasoula, Reshma Shah, et al.
British Journal of Cancer|February 16, 2019
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinomaDavid J Pinato, Matthew W Brown, Sebastian Trousil, et al.
Leukemia Research|May 9, 2009
Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasiaEleftheria Hatzimichael, Leonidas Benetatos, Aggeliki Dasoula, et al.
ACS Nano|April 13, 2010
Higher dispersion efficacy of functionalized carbon nanotubes in chemical and biological environmentsElena Heister, Constanze Lamprecht, Vera Neves, et al.
Anticancer Research|May 23, 2002
Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility studyHelen M Coley, Jean M Sargent, Christine J Williamson, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Anticancer Research|May 16, 2009
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancerPrasanna Sooriakumaran, Helen M Coley, Stephen B Fox, et al.
Pageof 4